Clinical trials: Urothelial Bladder Cancer
Bladder Cancer
Development of a Non-Invasive DNA Methylation-Based Assay System for the Risk Assessment of Urothelial Carcinoma
Bladder cancer ranks the ninth in worldwide cancer incidence. Approximate 90% of bladder cancer is the malignancy of urothelium tissues, the urothelial cancer (UC).
- Trial name
- NCT00867620
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Bladder Cancer, Urocystitis
A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China
The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose bladder cancer by comparing with clinical standard method…
- Conditions
- Bladder Cancer, Urocystitis, Urinary Bladder Stone, Urothelial Carcinoma
- Trial name
- NCT05337189
- Testing
- Urine DNA methylation analysis, medical imaging and/or cystoscopy and/or pathological examination
- Where
- China
- Volunteers
- 482 people, healthy volunteers welcome
- Sponsor
- Creative Biosciences (Guangzhou) Co., Ltd.
Urinary Bladder Neoplasms
Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer
Gemcitabine and cisplatin represent the standard first-line chemotherapy in metastatic bladder carcinoma. This regimen has replaced in most centers the MVAC combination showing a similar efficacy but less toxicity.
- Trial name
- NCT00818350
- Testing
- SUNITINIB
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Campania Younger Oncologists Association
Bladder Cancer, Biomarkers
Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder
To assess the persistence of bladder cancer-specific biomarkers in urine collected pre-operatively, in resected cancer tissue, and in urine collected post-operatively.
- Trial name
- NCT02745301
- Testing
- Collection of urine and bladder tumor specimens
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Invasive Bladder Cancer
HIPEC After Radical Cystectomy for High Risk Bladder Cancer
This is a non-randomized, non-blinded, pilot study administering hyperthermic intraperitoneal chemotherapy with Mitomycin-C in 10 men and women with muscle-invasive urothelial carcinoma of the bladder undergoing radical…
- Trial name
- NCT03514888
- Testing
- HIPEC
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Muscle Invasive Bladder Urothelial Carcinoma
Drug Screening Using IMD in Bladder Cancer
This research study involves implanting up to 4 microdevices, each small enough to fit inside the tip of a needle, into a tumor.
- Trial name
- NCT06204614
- Testing
- Implantable Micro-Device, Methotrexate, Carboplatin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Upper Urinary Tract Urothelial Carcinoma, Bladder Cancer
Single-Dose Intravesical Chemotherapy After Diagnostic URS
Study design This study is a Phase III, randomized, open-label, multi-center, global study to determine the efficacy of a single immediate intravesical chemotherapy instillation (SI) in the prophylaxis of intravesical recurrence…
- Trial name
- MINERVA (NCT05810623)
- Testing
- Intravesical Solution
- Where
- 2 sites in Austria
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- David D'Andrea
Cancer Risk, Cancer Predisposition Syndrome
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member…
- Conditions
- Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors
- Trial name
- NCT05463796
- Testing
- Samples
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Urothelial Cancer, Renal Pelvis Cancer
A Genotype-Phenotype Urothelial Cancer Registry
This study is being done to create a registry to help us learn more about urinary and other cancers. This will let us look at large groups of people who do and do not have this kind of cancer.
- Conditions
- Urothelial Cancer, Renal Pelvis Cancer, Ureter Cancer, Bladder Cancer
- Trial name
- NCT00902590
- Testing
- saliva sample and questionaire, saliva sample, questionaire
- Where
- 4 sites in United States
- Volunteers
- 3,519 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urothelial Carcinoma
Liquid Biospy for Urinary Cancers
The project aims to characterize the prognostic role of CTCs in Bladder cancer patients, with the specific aims to better stratify patients with non-muscle invasive bladder cancer at the first transurethral resection of tumor and…
- Trial name
- CIRCE (NCT06116396)
- Testing
- Genetic analysis on isolated cells
- Where
- Italy
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Muscle-invasive Bladder Urothelial Carcinoma
A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer
This is a prospective, open-label, single-center, single-arm clinical study. Plans to enroll 45 MIBC patients with clinical stage T2-T4aN0M0 and HER2-positive (IHC 1+/2+/3+) status.
- Trial name
- NCT07279597
- Testing
- RC48-ADC + Toripalimab
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Bladder Cancer
Expression of MCM5 in Urine in Patients With Urothelial Cancers
In patients with non-muscle-invasive bladder cancer, the development and introduction to the clinical practice of an adequately accurate biomarker may allow to limit the indications for performing control cystoscopy.
- Trial name
- NCT03796299
- Testing
- Assessment of expression of MCM5 in the urine (ADX Bladder)
- Where
- Poland
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Urothelial Carcinoma, Bladder Cancer
Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma
Clinical trial to evaluate the performance characteristics(sensitivity and specificity) of AnchorDx's urine DNA methylation/somatic mutation profiling assay for detecting urothelial carcinoma compared to pathology in patients.
- Trial name
- NCT04314245
- Testing
- Active Comparator: Pathology, Active Comparator: Clinical Diagnosis, Genetic test: AnchorDx's urine DNA methylation/somatic mutation profiling assay
- Where
- China
- Volunteers
- 1,170 people, healthy volunteers welcome
- Sponsor
- AnchorDx Medical Co., Ltd.
Non Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma
Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer
This is a prospective study to establish the analytical specificity of Bladder EpiCheck test in urine samples from healthy population and urology patients without prior history or evidence of bladder cancer.
- Trial name
- NCT06020807
- Testing
- Bladder EpiCheck
- Where
- United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Nucleix Ltd.
Localized Renal Pelvis and Ureter Urothelial Carcinoma, Malignant Solid Neoplasm
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
This study collects and studies tissue and blood samples from patients with prostate or bladder/urothelial cancer that has recurred (come back) at or near the same place as the original (primary) tumor or has spread to other…
- Conditions
- Localized Renal Pelvis and Ureter Urothelial Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues
- Trial name
- NCT01050504
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Washington
Hematuria, Acute Cystitis With Hematuria
Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed?
This prospective multicenter observational study evaluates whether women ≥50 years with isolated acute hemorrhagic cystitis (AHC) and macroscopic hematuria require full malignancy workup.
- Conditions
- Hematuria, Acute Cystitis With Hematuria, Bladder Cancer, Urothelial Carcinoma
- Trial name
- BLUSH (NCT07037589)
- Testing
- investigation setting (cystoscopy + CTU + cytology), Cystoscopy - CTU - cytology (if needed)
- Where
- Sweden
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Vastra Gotaland Region
Bladder Cancer, Urothelial Carcinoma
Research on the Accurate Diagnosis of Urinary Tract Tumors and the Development of Kits
Bladder cancer is the second most prevalent urological malignancy worldwide, with a high incidence and poor patient prognosis. Achieving early diagnosis and intervention for bladder cancer is one of the most important ways to…
- Trial name
- NCT06193941
- Testing
- RT-qPCR
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital
Urothelial Cancer, Cancer
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
The purpose of this study is to determine if analysis of DNA and protein material found in urine will be useful in the detection of urothelial cancer of the bladder and kidney.
- Conditions
- Urothelial Cancer, Cancer, Bladder Neoplasms, Urinary Bladder Cancer
- Trial name
- NCT00872495
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Lahey Clinic
Bladder Cancer, Urinary Tract Cancer
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
Background: Urothelial cancer is cancer of the bladder, ureter, and urethra. Researchers want to better understand what changes in a person s cells and genes cause this cancer to form.
- Conditions
- Bladder Cancer, Urinary Tract Cancer, Urothelial Cancer, Healthy Volunteers
- Trial name
- NCT02379429
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma
The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer
Recently, promising evidences that blocking PD-1 and PD-L1 is an efficacious way to treat advanced stage bladder cancer patients. Atezolimumab is the first PD-L1 inhibitor approved by US FDA for advanced UBC in June 2014.
- Trial name
- NCT03577132
- Testing
- Neoadjuvant atezolizumab
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital